RAGE Cancer Research Results

RAGE, Receptor for advanced glycation end-product: Click to Expand ⟱
Source:
Type:
RAGE (receptor for advanced glycation end-product) is thought to be associated with metastasis and poor prognosis of various types of cancer.
Cancer — Chronic Inflammation, Metastatic Signaling, and Therapy Resistance

Frequently upregulated (expression and/or activity) in tumors and surrounding stroma.
Core Oncogenic Programs Driven by RAGE
a. Chronic inflammation
-Sustained NF-κB activation
-Autocrine loops that perpetuate cytokine and chemokine production

b. Proliferation and survival
-Activation of MAPK/ERK and PI3K–AKT pathways
-Resistance to apoptosis under stress

c. Invasion and metastasis
-Induction of EMT-associated programs
-Matrix remodeling and enhanced motility

d. Angiogenesis
-Upregulation of pro-angiogenic factors in hypoxic niches

Therapeutic Implications
-Direct targeting: blocking RAGE or key ligand interactions can dampen chronic inflammation and invasion (conceptually attractive; clinical translation ongoing).
-Combination logic: RAGE pathway inhibition may sensitize tumors to chemotherapy, radiation, or immunotherapy by reducing stress-adaptive signaling.
-Biomarker role: elevated RAGE/ligand signatures can indicate inflammation-driven disease states.

RAGE is used as a clinical biomarker for inflammation state.


Scientific Papers found: Click to Expand⟱
8740- MGO,    Methylglyoxal induces ambience for cancer promotion in HepG2 cells via Warburg effect and promotes glycation
- in-vitro, Liver, HepG2
GLO-I↓, HAGH/GLO2↓, RAGE↑, AGEs↑, Hypoxia↑, ROS↑, GlucoseCon↑, GLUT1↑, HK2↑, PFK1↑, LDH↑, lactateProd↑, Glycolysis↑, Hif1a↑, Warburg↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

GLO-I↓, 1,   GlucoseCon↑, 1,   Glycolysis↑, 1,   HAGH/GLO2↓, 1,   HK2↑, 1,   lactateProd↑, 1,   PFK1↑, 1,   Warburg↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↑, 1,   Hypoxia↑, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

RAGE↑, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

LDH↑, 1,   RAGE↑, 1,  
Total Targets: 16

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: RAGE, Receptor for advanced glycation end-product
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:383  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page